<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39065261</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>Synbiotics as Treatment for Irritable Bowel Syndrome: A Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1493</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms12071493</ELocationID><Abstract><AbstractText>Irritable bowel syndrome is a persistent disturbance of the function of the gastrointestinal tract with a prevalence of about 11.2% in the population at large. While the etiology of the disorder remains unclear, there is mounting evidence that the disturbance of the gut microbiota is at least one contributing factor. This insight resulted in clinical trials investigating the therapeutic effects of products containing probiotic microorganisms. Most studies with IBS patients have evaluated the therapeutic effects of mono- and multi-strain probiotics, but only a few studies have investigated the efficacy of synbiotics (combinations of probiotic bacteria and one or more prebiotic components). This review summarizes the results from eight randomized, placebo-controlled clinical trials that investigated the efficacy of synbiotic preparations (three mono-strain and five multi-strain products) in adult IBS patients. While data remain sparse, some of the surveyed clinical trials have demonstrated interesting efficacy results in IBS patients. To allow a judgment of the role played by synbiotics in the treatment of IBS patients, more high-quality clinical trials are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sommermeyer</LastName><ForeName>Henning</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1991-9327</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#x105;tek</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2152-0876</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences, Calisia University, Nowy Swiat 4, 62-800 Kalisz, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword><Keyword MajorTopicYN="N">randomized clinical trials</Keyword><Keyword MajorTopicYN="N">synbiotics</Keyword></KeywordList><CoiStatement>H.S. received consulting fees from Vivatrex GmbH outside of the submitted work. The other author declares no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39065261</ArticleId><ArticleId IdType="pmc">PMC11278745</ArticleId><ArticleId IdType="doi">10.3390/microorganisms12071493</ArticleId><ArticleId IdType="pii">microorganisms12071493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford A.C., Sperber A.D., Corsetti M., Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675&#x2013;1688. doi: 10.1016/S0140-6736(20)31548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId><ArticleId IdType="pubmed">33049223</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C.J., Ford A.C. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020;8:473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA. 2021;325:865&#x2013;877. doi: 10.1001/jama.2020.22532. Erratum in JAMA 2021, 325, 1568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22532</ArticleId><ArticleId IdType="pubmed">33651094</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Chang L., Schneck S., Blackman C., Norton W.F., Norton N.J. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig. Dis. Sci. 2009;54:1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornkvist N.T., Aziz I., Whitehead W.E., Sperber A.D., Palsson O.S., Hreinsson J.P., Simr&#xe9;n M., T&#xf6;rnblom H. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United European Gastroenterol. J. 2021;9:1178&#x2013;1188. doi: 10.1002/ueg2.12153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ueg2.12153</ArticleId><ArticleId IdType="pmc">PMC8672084</ArticleId><ArticleId IdType="pubmed">34599559</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah E.D., Salwen-Deremer J.K., Gibson P.R., Muir J.G., Eswaran S., Chey W.D. Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome with Diarrhea: Cost-Benefit Analysis. Clin. Gastroenterol. Hepatol. 2022;20:136&#x2013;144. doi: 10.1016/j.cgh.2020.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.09.043</ArticleId><ArticleId IdType="pubmed">33010413</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood R., Law G.R., Ford A.C. Diagnosis of IBS: Symptoms, symptom-based criteria, biomarkers or &#x2018;psychomarkers&#x2019;? Nat. Rev. Gastroenterol. Hepatol. 2014;11:683&#x2013;691. doi: 10.1038/nrgastro.2014.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.127</ArticleId><ArticleId IdType="pubmed">25069544</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Chang L., Bellamy N., Gallo-Torres H.E., Lembo A., Mearin F., Norton N.J., Whorwell P. Severity in irritable bowel syndrome: A Rome Foundation Working Team report. Am. J. Gastroenterol. 2011;106:1749&#x2013;1759, quiz 1760. doi: 10.1038/ajg.2011.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2011.201</ArticleId><ArticleId IdType="pubmed">21747417</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake M.R., Raker J.M., Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2016;44:693&#x2013;703. doi: 10.1111/apt.13746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13746</ArticleId><ArticleId IdType="pubmed">27492648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin. Gastroenterol. Hepatol. 2012;10:712&#x2013;721. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5:908&#x2013;917. doi: 10.1016/S2468-1253(20)30217-X. Erratum in Lancet Gastroenterol. Hepatol. 2020, 5, e8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren J., Spiller R. Bowel disorders. Gastroenterology. 2016;150:1393&#x2013;1407. doi: 10.1053/j.gastro.2016.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbara G., Feinle-Bisset C., Ghoshal U.C., Quigley E.M., Santos J., Vanner S., Vergnolle N., Zoetendal E.G. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016;18:S0016-5085(16)00219-5. doi: 10.1053/j.gastro.2016.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.028</ArticleId><ArticleId IdType="pubmed">27144620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2010;22:512&#x2013;519, e114-5. doi: 10.1111/j.1365-2982.2009.01427.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2009.01427.x</ArticleId><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerckhoffs A.P., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World. J. Gastroenterol. 2009;15:2887&#x2013;2892. doi: 10.3748/wjg.15.2887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.15.2887</ArticleId><ArticleId IdType="pmc">PMC2699007</ArticleId><ArticleId IdType="pubmed">19533811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassinen A., Krogius-Kurikka L., M&#xe4;kivuokko H., Rinttil&#xe4; T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24&#x2013;33. doi: 10.1053/j.gastro.2007.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2007.04.005</ArticleId><ArticleId IdType="pubmed">17631127</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J., Derrien M., T&#xf6;rnblom H., Brazeilles R., Cools-Portier S., Dor&#xe9; J., St&#xf6;rsrud S., Le Nev&#xe9; B., &#xd6;hman L., Simr&#xe9;n M. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology. 2017;152:111&#x2013;123. doi: 10.1053/j.gastro.2016.09.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.09.049</ArticleId><ArticleId IdType="pubmed">27725146</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinen E., Krogius-Kurikka L., Lyra A., Nikkil&#xe4; J., J&#xe4;&#xe4;skel&#xe4;inen A., Rinttil&#xe4; T., Vilpponen-Salmela T., von Wright A.J., Palva A. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World. J. Gastroenterol. 2010;16:4532&#x2013;4540. doi: 10.3748/wjg.v16.i36.4532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i36.4532</ArticleId><ArticleId IdType="pmc">PMC2945484</ArticleId><ArticleId IdType="pubmed">20857523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccherini C., Daniotti S., Bearzi C., Re I. Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis. Nutrients. 2022;14:2689. doi: 10.3390/nu14132689.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14132689</ArticleId><ArticleId IdType="pmc">PMC9268703</ArticleId><ArticleId IdType="pubmed">35807868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506&#x2013;514. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Geest A.M., Schukking I., Brummer R.J.M., van de Burgwal L.H.M., Larsen O.F.A. Comparing probiotic and drug interventions in irritable bowel syndrome: A meta-analysis of randomised controlled trials. Benef. Microbes. 2022;13:183&#x2013;194. doi: 10.3920/BM2021.0123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2021.0123</ArticleId><ArticleId IdType="pubmed">35848115</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu H.L., Xiao J.Y. The efficacy and safety of probiotics in patients with irritable bowel syndrome: Evidence based on 35 randomized controlled trials. Int. J. Surg. 2020;75:116&#x2013;127. doi: 10.1016/j.ijsu.2020.01.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2020.01.142</ArticleId><ArticleId IdType="pubmed">32014597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Zhang C., Zhang J., Sun F., Duan L. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front. Cell. Infect. Microbiol. 2022;12:859967. doi: 10.3389/fcimb.2022.859967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.859967</ArticleId><ArticleId IdType="pmc">PMC9010660</ArticleId><ArticleId IdType="pubmed">35433498</ArticleId></ArticleIdList></Reference><Reference><Citation>Chlebicz-Wojcik A., Slizewska K. Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules. 2021;11:1154. doi: 10.3390/biom11081154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11081154</ArticleId><ArticleId IdType="pmc">PMC8412098</ArticleId><ArticleId IdType="pubmed">34439821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W.X., Shi L.B., Zhou M.S., Wu J., Shi H.Y. Efficacy of probiotics, prebiotics and synbiotics in irritable bowel syndrome: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. J. Med. Microbiol. 2023;72:001758. doi: 10.1099/jmm.0.001758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001758</ArticleId><ArticleId IdType="pubmed">37772692</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale H.F., Rasmussen S.H., Asiller &#xd6;.&#xd6;., Lied G.A. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Re-view. Nutrients. 2019;11:2048. doi: 10.3390/nu11092048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11092048</ArticleId><ArticleId IdType="pmc">PMC6769995</ArticleId><ArticleId IdType="pubmed">31480656</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang D., Longgui N., Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: A network me-ta-analysis. Medicine. 2019;98:e16068. doi: 10.1097/MD.0000000000016068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016068</ArticleId><ArticleId IdType="pmc">PMC6635271</ArticleId><ArticleId IdType="pubmed">31277101</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie P., Luo M., Deng X., Fan J., Xiong L. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients. 2023;15:3856. doi: 10.3390/nu15173856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15173856</ArticleId><ArticleId IdType="pmc">PMC10490209</ArticleId><ArticleId IdType="pubmed">37686889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolida S., Gibson G.R. Synbiotics in health and disease. Annu. Rev. Food Sci. Technol. 2011;2:373&#x2013;393. doi: 10.1146/annurev-food-022510-133739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-food-022510-133739</ArticleId><ArticleId IdType="pubmed">22129388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J. Nutr. 1995;125:1401&#x2013;1412. doi: 10.1093/jn/125.6.1401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jn/125.6.1401</ArticleId><ArticleId IdType="pubmed">7782892</ArticleId></ArticleIdList></Reference><Reference><Citation>Davani-Davari D., Negahdaripour M., Karimzadeh I., Seifan M., Mohkam M., Masoumi S.J., Berenjian A., Ghasemi Y. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. 2019;8:92. doi: 10.3390/foods8030092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods8030092</ArticleId><ArticleId IdType="pmc">PMC6463098</ArticleId><ArticleId IdType="pubmed">30857316</ArticleId></ArticleIdList></Reference><Reference><Citation>Min Y.W., Park S.U., Jang Y.S., Kim Y.H., Rhee P.L., Ko S.H., Joo N., Kim S.I., Kim C.H., Chang D.K. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J. Gastroenterol. 2012;18:4563&#x2013;4569. doi: 10.3748/wjg.v18.i33.4563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i33.4563</ArticleId><ArticleId IdType="pmc">PMC3435782</ArticleId><ArticleId IdType="pubmed">22969230</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogha M., Esfahani M.Z., Zargarzadeh A.H. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: A randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed. Bench. 2014;7:156&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129566</ArticleId><ArticleId IdType="pubmed">25120896</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.H., Jang Y.S., Kang D., Kim H.S., Kim E.J., Park S.Y., Kim C.H., Min Y.W., Chang D.K. Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Gut Liver. 2023;17:100&#x2013;107. doi: 10.5009/gnl210478.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl210478</ArticleId><ArticleId IdType="pmc">PMC9840930</ArticleId><ArticleId IdType="pubmed">35611667</ArticleId></ArticleIdList></Reference><Reference><Citation>Shavakhi A., Minakari M., Farzamnia S., Peykar M.S., Taghipour G., Tayebi A., Hashemi H., Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv. Biomed. Res. 2014;3:140. doi: 10.4103/2277-9175.135157.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.135157</ArticleId><ArticleId IdType="pmc">PMC4139977</ArticleId><ArticleId IdType="pubmed">25161987</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello C., Tremolaterra F., Pascariello A., Ciacci C., Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int. J. Color. Dis. 2013;28:349&#x2013;358. doi: 10.1007/s00384-012-1552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-012-1552-1</ArticleId><ArticleId IdType="pmc">PMC3587687</ArticleId><ArticleId IdType="pubmed">22885882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.H., Cho D.Y., Lee S.H., Han K.S., Yang S.W., Kim J.H., Lee S.H., Kim S.M., Kim K.N. A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue. Korean J. Fam. Med. 2019;40:2&#x2013;8. doi: 10.4082/kjfm.17.0064.</Citation><ArticleIdList><ArticleId IdType="doi">10.4082/kjfm.17.0064</ArticleId><ArticleId IdType="pmc">PMC6351792</ArticleId><ArticleId IdType="pubmed">30360032</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kosikowski W., Szczerbinski M., Gantzel J., Cukrowska B. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study. Nutrients. 2020;12:1999. doi: 10.3390/nu12071999. doi: 10.3390/nu12071999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12071999</ArticleId><ArticleId IdType="doi">10.3390/nu12071999</ArticleId><ArticleId IdType="pmc">PMC7400954</ArticleId><ArticleId IdType="pubmed">32635661</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommermeyer H., Chmielowiec K., Bernatek M., Olszewski P., Kopczynski J., Piatek J. Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2024;16:1503. doi: 10.3390/nu16101503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu16101503</ArticleId><ArticleId IdType="pmc">PMC11123967</ArticleId><ArticleId IdType="pubmed">38794741</ArticleId></ArticleIdList></Reference><Reference><Citation>De Angelis C., Drazen J.M., Frizelle F.A., Haug C., Hoey J., Horton R., Kotzin S., Laine C., Marusic A., Overbeke A.J., et al. Clinical trial registration: A statement from the International Committee of Medical Journal Editors. Ann. Intern. Med. 2004;141:477&#x2013;478. doi: 10.7326/0003-4819-141-6-200409210-00109.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-141-6-200409210-00109</ArticleId><ArticleId IdType="pubmed">15355883</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>